AstraZeneca's Baxdrostat met the primary and all secondary endpoints in BaxHTN Phase III trial
Baxdrostat demonstrated a statistically significant and clinically meaningful reduction of systolic blood pressure compared with placebo
Baxdrostat demonstrated a statistically significant and clinically meaningful reduction of systolic blood pressure compared with placebo
To streamline complex medical writing workflows with GenAI
Emcure Pharmaceuticals successfully completes USFDA PAI of Oncology facility
Friesland Campina Professional’s innovative Kievit portfolio features fat powders, creamers, foamers, whipping agents, cake emulsifiers
It is intended for contrast enhancement in MRI scans
This year, 40 women students are participating, selected through a rigorous process evaluating academic merit, research interest, and socio-economic background
The Medical Countermeasures Strategy focuses on strengthening the EU’s preparedness for health crises
The FDA set a target action date of April 28, 2026, under the Prescription Drug User Fee Act
Takara Bio Europe will distribute MN’s Bioanalysis portfolio in Austria, Belgium, Denmark, France, Germany, Ireland, Luxembourg, Sweden, Switzerland, and the United Kingdom
The first project will focus on developing an AI-based platform for the sterically guided design of bispecific antibodies
Subscribe To Our Newsletter & Stay Updated